EQS-News: PharmaSGP continues its growth course in 2025

PharmaSGP continues its growth course in 2025

Gräfelfing, May 15, 2025 – The German OTC pharmaceutical company PharmaSGP Holding SE has made a successful start to 2025, achieving a 10.8% increase in revenues to €33.5 million in the first quarter based on preliminary, unaudited figures (prior-year quarter: €30.2 million). Compared to the previous year, adjusted earnings before interest, taxes, depreciation and amortization (adjusted EBITDA) rose from €8.9 million to €9.2 million in the first three months of 2025. The resulting adjusted EBITDA margin amounted to 27.5% (prior-year quarter: 29.4%).

CEO Peter Gerckens comments: "Thanks to our strong organic growth, we were able to further increase our revenues in the first three months of 2025. The continuation of the previous year's positive business development underlines the sustainable success of our platform strategy. Even in a persistently volatile economic environment, we are in a position to profitably expand our business activities."

CFO Michael Rudolf adds: "Our core markets in particular are proving to be a reliable driver of our high level of organic revenues. Due to high cash generation and efficient financial management, we have a strong financial basis. This enables us to drive organic growth in a targeted manner while maintaining sufficient headroom for potential M&A activities. Overall, we see ourselves very well positioned for another year of profitable growth."

For the current financial year 2025, the Management Board of PharmaSGP forecasts an increase in revenues in a range between €122.0 million and €128.0 million. Adjusted EBITDA is expected to be between €37.0 million and €39.0 million, which corresponds to an adjusted EBITDA margin of 28.9% to 32.0%. The forecast for the 2025 financial year takes into account, among other things, the continuing high level of uncertainty in the geopolitical and global economic situation. Further developments over the course of the year and the potential consequences for Germany and Europe cannot be conclusively assessed at this time.

PharmaSGP will publish its full statement for the first three months of 2025 on May 28, 2025.
 

OVERVIEW OF PRELIMINARY YEAR-ON-YEAR FIGURES

CONTACT

cometis AG
Jakob Hafer
Phone: +49-611-20585522
Email: ir@pharmasgp.com

ABOUT PHARMASGP HOLDING SE

PharmaSGP is a leading consumer health company with a diversified portfolio of over-the-counter (OTC) pharmaceuticals and other healthcare products that are marketed with a focus on the pharmacy distribution channel. These products are mostly based on natural active pharmaceutical ingredients with documented efficacy and few known side effects.

The Company’s core brands cover chronic indications, including rheumatic pain, nerve pain and other age-related ailments. In Germany, PharmaSGP is the market leader for systemic chemical-free pain remedies with its brand families RubaXX^® for rheumatic pain and Restaxil^® for neuralgic pain. Furthermore, PharmaSGP also offers leading products against sexual weakness and vertigo symptoms. Since introducing the first product from the current product portfolio in 2012, PharmaSGP has successfully established its business model in other European countries, including Austria, Italy, Belgium, Spain and France. In September 2021, the product portfolio was expanded by the brands Baldriparan^®, Formigran^®, Spalt^® and Kamol^®, thus also strengthening or developing the indications pain and sleep disorder. The sales territory was expanded to include Switzerland and Eastern Europe. In 2024, PharmaSGP generated revenues of €118.8 million at an adjusted EBITDA margin of 31.3%.

In order to further expand its competitive position, PharmaSGP plans to increase the number of indications covered by PharmaSGP’s product offering, increase PharmaSGP’s European footprint, and accelerate its growth strategy especially by capitalizing on selected M&A opportunities.